To reduce adverse drug events (ADEs), hospitals need a system to support them in
monitoring ADE occurrence routinely, rapidly, and at scale. Natural language processing …

Over the years, my colleagues and I have come to realise that the likelihood of
pharmaceutical drugs being able to diffuse through whatever unhindered phospholipid …

Background Genetic variability in the cytochrome P450 CYP2C9 constitutes an important
predictor for efficacy and safety of various commonly prescribed drugs, including coumarin …

Background To date, research on adverse drug reactions (ADRs) has focused on secondary
care, and there is a paucity of studies that have prospectively examined ADRs affecting …

Background Adverse drug reactions (ADRs) have continued to be a public health challenge
with significant clinical and healthcare costs. However, little is known regarding the …

The discovery of antifibrotic agents have resulted in advances in the therapeutic
management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone …

Recent medical advancements have increased life expectancy, leading to a surge in
patients affected by multiple chronic diseases and consequent polypharmacy, especially …

Adverse drug events (ADEs) account for a significant mortality, morbidity, and cost burden.
Pharmacogenetic testing has the potential to reduce ADEs and inefficacy. The objective of …

Aim This study aimed to reveal the current status of the literature on rational prescribing
training in undergraduate medical education. Methods This study followed the preferred …

Background: Women have been underrepresented in large clinical trials in hypertension,
and the incidence of adverse drug reactions by sex has been not sufficiently described …